Logo image of VALN

VALNEVA SE - ADR (VALN) Stock Fundamental Analysis

USA - NASDAQ:VALN - US92025Y1038 - ADR

10.15 USD
-0.03 (-0.29%)
Last: 9/22/2025, 9:12:24 PM
9.5 USD
-0.65 (-6.4%)
After Hours: 9/22/2025, 9:12:24 PM
Fundamental Rating

3

Overall VALN gets a fundamental rating of 3 out of 10. We evaluated VALN against 538 industry peers in the Biotechnology industry. VALN has a bad profitability rating. Also its financial health evaluation is rather negative. While showing a medium growth rate, VALN is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year VALN has reported negative net income.
VALN had a negative operating cash flow in the past year.
In the past 5 years VALN always reported negative net income.
The reported operating cash flow has been mixed in the past 5 years: VALN reported negative operating cash flow in multiple years.
VALN Yearly Net Income VS EBIT VS OCF VS FCFVALN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M -200M

1.2 Ratios

The Return On Assets of VALN (-18.09%) is better than 78.62% of its industry peers.
VALN has a Return On Equity of -45.87%. This is in the better half of the industry: VALN outperforms 68.03% of its industry peers.
Industry RankSector Rank
ROA -18.09%
ROE -45.87%
ROIC N/A
ROA(3y)-15.85%
ROA(5y)-14.17%
ROE(3y)-50.34%
ROE(5y)-55.45%
ROIC(3y)N/A
ROIC(5y)N/A
VALN Yearly ROA, ROE, ROICVALN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20 -40 -60 -80

1.3 Margins

VALN has a Gross Margin of 48.94%. This is in the better half of the industry: VALN outperforms 75.09% of its industry peers.
VALN's Gross Margin has declined in the last couple of years.
VALN does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 48.94%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.2%
GM growth 5Y-7.06%
VALN Yearly Profit, Operating, Gross MarginsVALN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 -40 60 -60

More info and screens

3

2. Health

2.1 Basic Checks

VALN does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for VALN has been increased compared to 1 year ago.
The number of shares outstanding for VALN has been increased compared to 5 years ago.
Compared to 1 year ago, VALN has an improved debt to assets ratio.
VALN Yearly Shares OutstandingVALN Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
VALN Yearly Total Debt VS Total AssetsVALN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

Based on the Altman-Z score of 0.58, we must say that VALN is in the distress zone and has some risk of bankruptcy.
VALN's Altman-Z score of 0.58 is fine compared to the rest of the industry. VALN outperforms 61.52% of its industry peers.
VALN has a Debt/Equity ratio of 0.80. This is a neutral value indicating VALN is somewhat dependend on debt financing.
With a Debt to Equity ratio value of 0.80, VALN is not doing good in the industry: 74.54% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 0.8
Debt/FCF N/A
Altman-Z 0.58
ROIC/WACCN/A
WACC7.93%
VALN Yearly LT Debt VS Equity VS FCFVALN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M -200M

2.3 Liquidity

VALN has a Current Ratio of 2.27. This indicates that VALN is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of VALN (2.27) is worse than 71.75% of its industry peers.
VALN has a Quick Ratio of 1.77. This is a normal value and indicates that VALN is financially healthy and should not expect problems in meeting its short term obligations.
VALN has a Quick ratio of 1.77. This is in the lower half of the industry: VALN underperforms 77.32% of its industry peers.
Industry RankSector Rank
Current Ratio 2.27
Quick Ratio 1.77
VALN Yearly Current Assets VS Current LiabilitesVALN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

More info and screens

5

3. Growth

3.1 Past

The earnings per share for VALN have decreased strongly by -95.65% in the last year.
The Revenue has grown by 31.49% in the past year. This is a very strong growth!
Measured over the past years, VALN shows a small growth in Revenue. The Revenue has been growing by 6.09% on average per year.
EPS 1Y (TTM)-95.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%56.25%
Revenue 1Y (TTM)31.49%
Revenue growth 3Y-21.31%
Revenue growth 5Y6.09%
Sales Q2Q%26.98%

3.2 Future

VALN is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 70.06% yearly.
Based on estimates for the next years, VALN will show a quite strong growth in Revenue. The Revenue will grow by 18.12% on average per year.
EPS Next Y-609.41%
EPS Next 2Y-99.8%
EPS Next 3Y111.41%
EPS Next 5Y70.06%
Revenue Next Year3.32%
Revenue Next 2Y13.24%
Revenue Next 3Y28.12%
Revenue Next 5Y18.12%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
VALN Yearly Revenue VS EstimatesVALN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 100M 200M 300M 400M 500M
VALN Yearly EPS VS EstimatesVALN Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 1 -1 2 -2 3

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

VALN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year VALN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
VALN Price Earnings VS Forward Price EarningsVALN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
VALN Per share dataVALN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2 3 4

4.3 Compensation for Growth

A more expensive valuation may be justified as VALN's earnings are expected to grow with 111.41% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-99.8%
EPS Next 3Y111.41%

More info and screens

0

5. Dividend

5.1 Amount

VALN does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

VALNEVA SE - ADR

NASDAQ:VALN (9/22/2025, 9:12:24 PM)

After market: 9.5 -0.65 (-6.4%)

10.15

-0.03 (-0.29%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-12 2025-08-12/bmo
Earnings (Next)11-20 2025-11-20
Inst Owners23.31%
Inst Owner Change569.6%
Ins Owners0.22%
Ins Owner ChangeN/A
Market Cap863.07M
Analysts83.33
Price Target16.93 (66.8%)
Short Float %0.02%
Short Ratio0.15
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)59.78%
Min EPS beat(2)56.68%
Max EPS beat(2)62.87%
EPS beat(4)3
Avg EPS beat(4)14.13%
Min EPS beat(4)-115.24%
Max EPS beat(4)62.87%
EPS beat(8)4
Avg EPS beat(8)3.13%
EPS beat(12)6
Avg EPS beat(12)-23.48%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)21.69%
Min Revenue beat(2)16.4%
Max Revenue beat(2)26.97%
Revenue beat(4)3
Avg Revenue beat(4)10.09%
Min Revenue beat(4)-4.78%
Max Revenue beat(4)26.97%
Revenue beat(8)4
Avg Revenue beat(8)1.3%
Revenue beat(12)7
Avg Revenue beat(12)19.63%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-4.86%
PT rev (3m)-1.9%
EPS NQ rev (1m)2.43%
EPS NQ rev (3m)-56.11%
EPS NY rev (1m)-4.08%
EPS NY rev (3m)-5.87%
Revenue NQ rev (1m)-0.54%
Revenue NQ rev (3m)-16.53%
Revenue NY rev (1m)-0.68%
Revenue NY rev (3m)-3.35%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.51
P/FCF N/A
P/OCF N/A
P/B 3.93
P/tB 4.51
EV/EBITDA N/A
EPS(TTM)-1
EYN/A
EPS(NY)-0.62
Fwd EYN/A
FCF(TTM)-0.37
FCFYN/A
OCF(TTM)-0.16
OCFYN/A
SpS4.04
BVpS2.58
TBVpS2.25
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -18.09%
ROE -45.87%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 48.94%
FCFM N/A
ROA(3y)-15.85%
ROA(5y)-14.17%
ROE(3y)-50.34%
ROE(5y)-55.45%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.2%
GM growth 5Y-7.06%
F-Score4
Asset Turnover0.62
Health
Industry RankSector Rank
Debt/Equity 0.8
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 71.71%
Cap/Sales 5.14%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.27
Quick Ratio 1.77
Altman-Z 0.58
F-Score4
WACC7.93%
ROIC/WACCN/A
Cap/Depr(3y)101.58%
Cap/Depr(5y)231.17%
Cap/Sales(3y)9.04%
Cap/Sales(5y)14.31%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-95.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%56.25%
EPS Next Y-609.41%
EPS Next 2Y-99.8%
EPS Next 3Y111.41%
EPS Next 5Y70.06%
Revenue 1Y (TTM)31.49%
Revenue growth 3Y-21.31%
Revenue growth 5Y6.09%
Sales Q2Q%26.98%
Revenue Next Year3.32%
Revenue Next 2Y13.24%
Revenue Next 3Y28.12%
Revenue Next 5Y18.12%
EBIT growth 1Y-49.96%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-262.99%
EBIT Next 3Y35.74%
EBIT Next 5Y30.38%
FCF growth 1Y88.22%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y94.27%
OCF growth 3YN/A
OCF growth 5YN/A